In a recent study published in the journal JAMA Network Open, researchers determined that diabetes, high blood pressure, and new-onset hyperlipidemia, all cardiometabolic disorders in adult patients with coronavirus disease 2019 (COVID-19) are under treatment in California, United States. of America (USA) between March 2020 and June 2022.
They used a self-stressing cross-exposure design to estimate the chances of a new cardiometabolic disorder occurring 90 days after or before COVID-19.
The threat of emerging cardiometabolic diseases was greatest at the beginning of the COVID-19 pandemic. However, studies have not yet explored whether this threat persists in the era of dominance of the less virulent variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV). -2) Omicron. It is also unclear whether those threats have been reduced due to COVID-19 vaccination.
In the existing study, researchers learned of newly reported cardiometabolic diagnoses before or after a patient’s first episode of COVID-19. Angeles, United States.
They took into account all time-varying confounding resulting from disruptions in healthcare use during the pandemic when estimating the likelihood of a new onset of cardiometabolic disorder. Therefore, they compared its effects with new baseline diagnoses, for example, a urinary tract infection, which represents a marker of healthcare use unrelated to COVID-19.
The team used a multivariate logistic regression style to estimate the odds ratio (OR) and 95% confidence period (CI) for a new cardiometabolic diagnosis rather than an initial rediagnosis. The test OR estimates lasted 90 days before and after SARS-CoV. -2, and study design adjusted for each participant’s age, sex, duration of infection (before and after Omicron), and SARS-CoV-2 vaccination status.
In the existing cohort study, the researchers analyzed 23,709 patients aged 47. 4 years who experienced one or more episodes of COVID-19. There were 12,706 women, 10,981 men, and 22 of unknown sex, respectively.
The effects of the study matched the findings of another recent meta-analysis. They showed that SARS-CoV-2 infection increases the risk of new-onset diabetes and other cardiometabolic diseases. As a result, the rate of occurrence of these diseases is higher in the control organization 90 days after SARS-CoV-2 infection compared to before infection, with an adjusted multivariate style presenting an OR equivalent to 1. 58 and a 95% CI. In addition, the odds were highest for diabetes, followed by hypertension. .
Interestingly, COVID-19 has a higher chance of baseline diagnoses than hyperlipidemia and hypertension. In addition, the interaction between prestige of vaccination and new-onset diabetes is statistically non-significant, with OR = 0. 59, 95% CI. However, the threat of diabetes is higher in other unvaccinated people than in other vaccinated people (OR 1. 78 compared to 1. 07; 95% CI, suggesting that COVID-19 vaccination is beneficial. Sociodemographic factors, such as age, sex, and pre-existing cardiovascular conditions, also had no obvious interaction with new-onset cardiometabolic diagnosis before or after SARS-CoV-2 infection in any model.
Even after accounting for confounding factors that vary over time, the threat of a resurgence of cardiometabolic diagnosis persisted during the period of Omicron dominance. In conclusion, the studies did not explain the mechanisms that contribute to the threat of diabetes after SARS-CoV-2 infection. However, some researchers have proposed that persistent inflammation contributes to insulin resistance amplifying the threat of diabetes.
Therefore, there is a pressing need for more studies exploring the side effects of COVID-19 and how COVID-19 vaccination may only be the risk of new cardiometabolic diseases.
Written by
Neha is a virtual marketing professional founded in Gurugram, India. He holds a master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. He has enjoyed preclinical studies as part of his assignment of studies in Toxicology Decomposition from the prestigious Central Drug Research Institute (CDRI), Lucknow, India. He also holds a certification in C programming.
Use one of the following to cite this article in your essay, article, or report:
AAP
Mathur, Neha. (2023, February 15). COVID-19 is linked to increased risk of diabetes and hypertension. Actualités-Médicale. Retrieved February 16, 2023, from https://www. news-medical. net/news/20230215/COVID-19-is-related-with-upper-diabetes-and-hipertension-threat. aspx.
deputy
Mathur, Neha. ” COVID-19 is linked to an increased threat of diabetes and hypertension. ” Actualités-Médicale. February 16, 2023. .
Chicago
Mathur, Neha. ” COVID-19 is linked to an increased threat of diabetes and hypertension. “Medical news. -diabetes-and-hypertension-threat. aspx. (accessed February 16, 2023).
Harvard
Mathur, Neha. 2023. COVID-19 is linked to an increased threat of diabetes and hypertension. News-Medical, accessed February 16, 2023, https://www. news-medical. net/news/20230215/COVID-19- is-related-to-the-superior-diabetes-e-hypertension-threat. aspx.
News-Medical. net – An AZoNetwork website
Owned and operated through AZoNetwork, © 2000-2023